These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19104507)

  • 21. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
    Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
    Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery.
    Nasso G; Piancone F; Bonifazi R; Romano V; Visicchio G; De Filippo CM; Impiombato B; Fiore F; Bartolomucci F; Alessandrini F; Speziale G
    Ann Thorac Surg; 2009 Nov; 88(5):1520-6. PubMed ID: 19853105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
    Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
    J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of interleukin-12 expressing dendritic cells for the treatment of animal model of leukemia.
    Tsai BY; Lin YL; Chiang BL
    Exp Biol Med (Maywood); 2009 Aug; 234(8):952-60. PubMed ID: 19491372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities.
    Ho MY; Leu SJ; Sun GH; Tao MH; Tang SJ; Sun KH
    J Immunol; 2009 Nov; 183(10):6217-26. PubMed ID: 19841177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
    Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
    Gannon PO; Poisson AO; Delvoye N; Lapointe R; Mes-Masson AM; Saad F
    J Immunol Methods; 2009 Aug; 348(1-2):9-17. PubMed ID: 19552894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally.
    Fewell JG; Matar MM; Rice JS; Brunhoeber E; Slobodkin G; Pence C; Worker M; Lewis DH; Anwer K
    J Gene Med; 2009 Aug; 11(8):718-28. PubMed ID: 19507172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.
    Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM
    J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
    Evans S; Dizeyi N; Abrahamsson PA; Persson J
    Anticancer Res; 2009 Oct; 29(10):3917-24. PubMed ID: 19846929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does topical haemostatic agent have an adverse effect on the function of the prostatic neurovascular bundle?
    Zeltser I; Dugi D; Gupta A; Park S; Kabbani W; Cadeddu J
    BJU Int; 2008 Sep; 102(8):1005-7. PubMed ID: 18564131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model.
    Barken I; Geller J; Rogosnitzky M
    Anticancer Res; 2008; 28(6A):3701-4. PubMed ID: 19189652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
    Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative safety and efficacy of topical hemostatic agents in a rat neurosurgical model.
    Ereth MH; Schaff M; Ericson EF; Wetjen NM; Nuttall GA; Oliver WC
    Neurosurgery; 2008 Oct; 63(4 Suppl 2):369-72; discussion 372. PubMed ID: 18981845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted IL-24 gene therapy inhibits cancer recurrence after liver tumor resection by inducing tumor cell apoptosis in nude mice.
    Yang YJ; Chen DZ; Li LX; Sheng QS; Jin ZK; Zhao DF
    Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):174-8. PubMed ID: 19357032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation.
    Makinde AY; Luo-Owen X; Rizvi A; Crapo JD; Pearlstein RD; Slater JM; Gridley DS
    Anticancer Res; 2009 Jan; 29(1):107-18. PubMed ID: 19331139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.